494 related articles for article (PubMed ID: 9816285)
1. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
[TBL] [Abstract][Full Text] [Related]
2. EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer.
Hui R; Campbell DH; Lee CS; McCaul K; Horsfall DJ; Musgrove EA; Daly RJ; Seshadri R; Sutherland RL
Oncogene; 1997 Sep; 15(13):1617-23. PubMed ID: 9380415
[TBL] [Abstract][Full Text] [Related]
3. [Invasive ductal carcinoma of the breast: study of the number of copies of the CCND1 gene and chromosome 11 using fluorescence in situ hybridization (FISH) in comparison with expression of cyclin D1 protein and estrogen receptors (ER alpha) with immunohistochemical detection].
Mrhalová M; Kodet R; Strnad P
Cas Lek Cesk; 2002 Nov; 141(22):708-14. PubMed ID: 12532908
[TBL] [Abstract][Full Text] [Related]
4. EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival.
Hui R; Ball JR; Macmillan RD; Kenny FS; Prall OW; Campbell DH; Cornish AL; McClelland RA; Daly RJ; Forbes JF; Blamey RW; Musgrove EA; Robertson JF; Nicholson RI; Sutherland RL
Oncogene; 1998 Aug; 17(8):1053-9. PubMed ID: 9747885
[TBL] [Abstract][Full Text] [Related]
5. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
Champème MH; Bièche I; Hacène K; Lidereau R
Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer.
Kenny FS; Hui R; Musgrove EA; Gee JM; Blamey RW; Nicholson RI; Sutherland RL; Robertson JF
Clin Cancer Res; 1999 Aug; 5(8):2069-76. PubMed ID: 10473088
[TBL] [Abstract][Full Text] [Related]
7. PPFIA1 and CCND1 are frequently coamplified in breast cancer.
Dancau AM; Wuth L; Waschow M; Holst F; Krohn A; Choschzick M; Terracciano L; Politis S; Kurtz S; Lebeau A; Friedrichs K; Wencke K; Monni O; Simon R
Genes Chromosomes Cancer; 2010 Jan; 49(1):1-8. PubMed ID: 19787783
[TBL] [Abstract][Full Text] [Related]
8. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression.
Akervall JA; Michalides RJ; Mineta H; Balm A; Borg A; Dictor MR; Jin Y; Loftus B; Mertens F; Wennerberg JP
Cancer; 1997 Jan; 79(2):380-9. PubMed ID: 9010112
[TBL] [Abstract][Full Text] [Related]
9. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
10. INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis.
Hui R; Macmillan RD; Kenny FS; Musgrove EA; Blamey RW; Nicholson RI; Robertson JF; Sutherland RL
Clin Cancer Res; 2000 Jul; 6(7):2777-87. PubMed ID: 10914724
[TBL] [Abstract][Full Text] [Related]
11. High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer.
Zaharieva BM; Simon R; Diener PA; Ackermann D; Maurer R; Alund G; Knönagel H; Rist M; Wilber K; Hering F; Schönenberger A; Flury R; Jäger P; Fehr JL; Mihatsch MJ; Gasser T; Sauter G; Toncheva DI
J Pathol; 2003 Dec; 201(4):603-8. PubMed ID: 14648664
[TBL] [Abstract][Full Text] [Related]
12. Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer.
Hui R; Cornish AL; McClelland RA; Robertson JF; Blamey RW; Musgrove EA; Nicholson RI; Sutherland RL
Clin Cancer Res; 1996 Jun; 2(6):923-8. PubMed ID: 9816251
[TBL] [Abstract][Full Text] [Related]
13. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification.
Jirström K; Stendahl M; Rydén L; Kronblad A; Bendahl PO; Stål O; Landberg G
Cancer Res; 2005 Sep; 65(17):8009-16. PubMed ID: 16140974
[TBL] [Abstract][Full Text] [Related]
14. HER-2/neu amplification predicts poor survival in node-positive breast cancer.
Borg A; Tandon AK; Sigurdsson H; Clark GM; Fernö M; Fuqua SA; Killander D; McGuire WL
Cancer Res; 1990 Jul; 50(14):4332-7. PubMed ID: 1973070
[TBL] [Abstract][Full Text] [Related]
15. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
Naidu R; Wahab NA; Yadav MM; Kutty MK
Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618
[TBL] [Abstract][Full Text] [Related]
16. Cyclin D1 gene amplification in human laryngeal squamous cell carcinomas: prognostic significance and clinical implications.
Bellacosa A; Almadori G; Cavallo S; Cadoni G; Galli J; Ferrandina G; Scambia G; Neri G
Clin Cancer Res; 1996 Jan; 2(1):175-80. PubMed ID: 9816104
[TBL] [Abstract][Full Text] [Related]
17. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer.
Berns EM; Klijn JG; van Putten WL; van Staveren IL; Portengen H; Foekens JA
Cancer Res; 1992 Mar; 52(5):1107-13. PubMed ID: 1737370
[TBL] [Abstract][Full Text] [Related]
18. Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene.
Zukerberg LR; Yang WI; Gadd M; Thor AD; Koerner FC; Schmidt EV; Arnold A
Mod Pathol; 1995 Jun; 8(5):560-7. PubMed ID: 7675778
[TBL] [Abstract][Full Text] [Related]
19. ERBB2 amplification in breast cancer with a high rate of proliferation.
Borg A; Baldetorp B; Fernö M; Killander D; Olsson H; Sigurdsson H
Oncogene; 1991 Jan; 6(1):137-43. PubMed ID: 1671531
[TBL] [Abstract][Full Text] [Related]
20. Constitutive overexpression of cyclin D1 does not prevent inhibition of hormone-responsive human breast cancer cell growth by antiestrogens.
Pacilio C; Germano D; Addeo R; Altucci L; Petrizzi VB; Cancemi M; Cicatiello L; Salzano S; Lallemand F; Michalides RJ; Bresciani F; Weisz A
Cancer Res; 1998 Mar; 58(5):871-6. PubMed ID: 9500441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
